# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

# Single Technology Appraisal (STA)

# Ticagrelor for the treatment of acute coronary syndrome

#### Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
AstraZeneca (ticagelor)	Board of Community Health Councils     in Wales
<ul> <li>Patient/carer groups</li> <li>Action Heart</li> <li>Afiya Trust</li> <li>Black Health Agency</li> <li>Blood Pressure Association</li> <li>British Cardiac Patients Association</li> <li>Chinese National Healthy Living Centre</li> <li>Grown Up Congenital Heart Patients Association (GUCH)</li> <li>Counsel and Care</li> </ul>	<ul> <li>British Cardiovascular Industry Association</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Commissioning Support Appraisals Service</li> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>Medicines and Healthcare products Regulatory Agency (MHRA)</li> <li>National Association of Primary Care</li> </ul>
<ul> <li>Equalities National Council</li> <li>Heart Care Partnership (UK)</li> <li>HEART UK</li> <li>Muslim Council of Britain</li> <li>Muslim Health Network</li> <li>Network of Sikh Organisations UK</li> <li>South Asian Health Foundation</li> </ul>	<ul> <li>Public Health Wales NHS Trust</li> <li>NHS Alliance</li> <li>NHS Confederation</li> <li>NHS Commercial Medicines Unit</li> <li>NHS Quality Improvement Scotland</li> <li>Scottish Medicines Consortium</li> </ul>
<ul> <li>Specialised Healthcare Alliance</li> <li><u>Professional groups</u></li> <li>British Association for Nursing in Cardiac Care</li> <li>British Association for Services to the Elderly</li> <li>British Cardiovascular Intervention Society (BCIS)</li> </ul>	<ul> <li><u>Comparator manufacturer(s)</u></li> <li>Activis (clopidogrel)</li> <li>Arrow Generics (clopidogrel)</li> <li>Bristol-Myers Squibb (clopidogrel)</li> <li>Daiichi Sankyo (prasugrel)</li> <li>Eli Lilly (prasugrel)</li> <li>Sanofi-Aventis (clopidogrel)</li> <li>Teva UK (clopidogrel)</li> </ul>
<ul> <li>British Cardiovascular Society</li> <li>British Geriatrics Society</li> <li>British Heart Foundation</li> <li>British Society for Heart Failure</li> <li>Heart Rhythm UK</li> <li>National Heart Forum</li> <li>Primary Care Cardiovascular Society</li> <li>Royal College of General</li> </ul>	<ul> <li><u>Relevant research groups</u></li> <li>British Society for Cardiovascular Research</li> <li>Cardiovascular Diseases Specialist Library (CVDSL)</li> <li>Central Cardiac Audit Database</li> <li>Cochrane Heart Group</li> <li>National Institute for Health Research</li> <li>Policy Research Institute on Ageing</li> </ul>

Matrix for the technology appraisal of ticagrelor for the treatment of acute coronary syndrome

## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## Single Technology Appraisal (STA)

Consultees	Commentators (no right to submit or appeal)
<ul> <li>Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine – Intellectual Disabilities Forum</li> <li>Society for Cardiological Science and Technology</li> <li>United Kingdom Clinical Pharmacy Association</li> <li>Vascular Society</li> <li>Department of Health</li> <li>Bradford and Airedale Teaching PCT</li> <li>Oxfordshire PCT</li> <li>Welsh Government Assembly</li> </ul>	<ul> <li>and Ethnicity</li> <li>Research Institute for the Care of Older People</li> <li>Evidence Review Group</li> <li>Liverpool Reviews &amp; Implementation Group, University of Liverpool</li> <li>National Coordinating Centre for Health Technology Assessment</li> <li><u>Associated Guideline Groups</u></li> <li>National Collaborating Centre for Chronic Conditions</li> <li>National Collaborating Centre for Primary Care</li> <li><u>Associated Public Health Groups</u></li> <li>none</li> </ul>

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

## **Definitions:**

# NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

# Single Technology Appraisal (STA)

#### **Consultees**

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### **Commentators**

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

<sup>&</sup>lt;sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.